20 april 2021: Bron: Annals of Oncology

Moleculaire veranderingen en PD-L1 expressie waarden geven een zogeheten gecombineerde positieve score (CPS). Uit een studie onder 2518 patiënten met gastro-oesofageale adenocarcinoom uitgevoerd door CARIS blijkt dat bij patiënten met actief herstel van mismatch en microsatellietstabiele ziekte de KRAS-, TP53- en RAS-MAPK-pathway-mutaties geassocieerd werden met een hogere gecombineerde positieve score (CPS). 

Mutaties in de RAS-MAPK-pathway vertoonden een gunstige voorspelling voor een betere algehele overleving (OS), terwijl TP53-mutaties geassocieerd waren met een kortere algehele overleving (OS) in deze groep met behandeling met immuuntherapie met anti-PD medicijnen.

Uit het studieabstract:

Highlights:

  • 1.
    GEA tumors with mutations in KRASTP53 and RAS-MAPK pathway are associated with high PD-L1 CPS in the pMMR&MSS subgroup.
  • 2.
    RAS-MAPK pathway alteration may be a positive predictor and TP53 mutation a negative predictor for ICI efficacy in GEA.
  • 3.
    RAS-MAPK pathway alteration and TP53 mutation are positively and negatively, respectively, associated with tumor immunity.
Voor het studierapport moet betaald worden maar hier het abstract van de studie met enkele gerelateerde andere studies.

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy



Abstract

Purpose

The impact of molecular alterations on PD-L1 combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features of tumors with different CPSs in GEAs.

Patients and methods

Genomic alterations of 2,518 GEAs were compared in three groups (PD-L1 CPS≥10, high; CPS=1-9, intermediate; CPS<1, low) using next-generation sequencing. We assessed the impact of gene mutations on the efficacy of immune checkpoint inhibitors (ICIs) and tumor immune environment based on MSKCC and TCGA databases.

Results

CPS-high, intermediate, and low were seen in 18%, 54% and 28% of GEAs respectively. PD-L1 positivity was less prevalent in women and in tissues derived from metastatic sites. PD-L1 CPS was positively associated with dMMR/MSI-H, but independent of TMB distribution. Tumors with mutations in KRASTP53 and RAS-MAPK pathway were associated with higher PD-L1 CPSs in the pMMR&MSS subgroup. Patients with RAS-MAPK pathway alterations had longer overall survival (OS) from ICIs compared to wildtype patients [27 vs. 13 months, hazard ratio (HR)=0.36, 95% confidence interval (CI): 0.19-0.7, p=0.016] and a similar trend was observed in the MSS subgroup (p=0.11). In contrast, patients with TP53 mutations had worse OS from ICIs compared to TP53-wildtype patients in the MSS subgroup (5 vs. 21 months, HR=2.39, 95%CI: 1.24-4.61, p=0.016).

Conclusion

This is the largest study to investigate the distinct genomic landscapes of GEAs with different PD-L1 CPSs. Our data may provide novel insights for patient selection using mutations in TP53 and RAS-MAPK pathway and the development of rational combination immunotherapies in GEAs.

References:

    • Fashoyin Aje L.
    • Donoghue M.
    • Chen H.
    • et al.
    FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1.
    The Oncologist. 2018; 24103-109
    • Wainberg CSFJ Zev A.
    Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.
    J CLIN ONCOL. 2020; (4_suppl)427
    • Shitara K.
    • Van Cutsem E.
    • Bang Y.
    • et al.
    Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer.
    JAMA ONCOL. 2020;
    • Moehler KSMG M.
    Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study.
    ANN ONCOL. 2020; (suppl_4)S1142-S1215
    • Boku N.
    • Ryu M.H.
    • Kato K.
    • et al.
    Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    ANN ONCOL. 2019; 30250-258
  1. Comprehensive molecular characterization of gastric adenocarcinoma.
    NATURE. 2014; 513202-209
    • Kim S.T.
    • Cristescu R.
    • Bass A.J.
    • et al.
    Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
    NAT MED. 2018; 241449-1458
    • Xie T.
    • Liu Y.
    • Zhang Z.
    • et al.
    Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
    J IMMUNOTHER. 2020; 43139-144
    • Menyhárt O.
    • Pongor L.S.
    • Győrffy B.
    Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer.
    FRONT PHARMACOL. 2019; 9
    • Liu X.
    • Choi M.G.
    • Kim K.
    • et al.
    High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Pathology - Research and Practice. 2020; 152881
    • Kim Y.B.
    • Ahn J.M.
    • Bae W.J.
    • Sung C.O.
    • Lee D.
    Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    INT J CANCER. 2019; 145916-926
    • Salem M.E.
    • Puccini A.
    • Xiu J.
    • et al.
    Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
    The Oncologist. 2018; 231319-1327
    • Tokunaga R.
    • Xiu J.
    • Johnston C.
    • et al.
    Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    CLIN CANCER RES. 2019; 253096-3103
    • Salem M.E.
    • Puccini A.
    • Grothey A.
    • et al.
    Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
    MOL CANCER RES. 2018; 16805-812
    • Sanchez-Vega F.
    • Mina M.
    • Armenia J.
    • et al.
    Oncogenic Signaling Pathways in The Cancer Genome Atlas.
    CELL. 2018; 173321-337
    • Schoenfeld A.J.
    • Rizvi H.
    • Bandlamudi C.
    • et al.
    Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
    ANN ONCOL. 2020;
    • de la Roche M.
    • Worm J.
    • Bienz M.
    The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
    BMC CANCER. 2008; 8199
    • Zhang Y.
    • Wang S.
    • Kang W.
    • et al.
    CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation.
    ONCOGENE. 2018; 373485-3500
    • Kulangara K.
    • Zhang N.
    • Corigliano E.
    • et al.
    Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
    ARCH PATHOL LAB MED. 2019; 143330-337
    • Huang K.
    • Mashl R.J.
    • Wu Y.
    • et al.
    Pathogenic Germline Variants in 10,389 Adult Cancers.
    CELL. 2018; 173355-370
    • Andrew Eugene Hendifar E.M.B.C.
    Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.
    J CLIN ONCOL. 2020; 154641
    • Cha J.
    • Chan L.
    • Li C.
    • Hsu J.L.
    • Hung M.
    Mechanisms Controlling PD-L1 Expression in Cancer.
    MOL CELL. 2019; 76359-370
    • O Malley D.P.
    • Yang Y.
    • Boisot S.
    • et al.
    Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases.
    MODERN PATHOL. 2019; 32929-942
    • Conforti F.
    • Pala L.
    • Bagnardi V.
    • et al.
    Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    The Lancet Oncology. 2018; 19737-746
    • Luchini C.
    • Bibeau F.
    • Ligtenberg M.
    • et al.
    ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    ANN ONCOL. 2019; 301232-1243
    • Kalbasi A.
    • Ribas A.
    Tumour-intrinsic resistance to immune checkpoint blockade.
    NAT REV IMMUNOL. 2020; 2025-39
    • Pan L.N.
    • Ma Y.F.
    • Li Z.
    • Hu J.A.
    • Xu Z.H.
    KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer.
    CELL BIOL INT. 2021;
    • Glorieux C.
    • Xia X.
    • He Y.
    • et al.
    Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling.
    REDOX BIOL. 2021; 38101780
    • Sumimoto H.
    • Takano A.
    • Teramoto K.
    • Daigo Y.
    RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
    PLOS ONE. 2016; 11e166626
    • Coelho M.A.
    • de Carné Trécesson S.
    • Rana S.
    • et al.
    Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
    IMMUNITY. 2017; 471083-1099
    • Dong Z.
    • Zhong W.
    • Zhang X.
    • et al.
    Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
    CLIN CANCER RES. 2017; 233012-3024
    • Hashimoto S.
    • Furukawa S.
    • Hashimoto A.
    • et al.
    ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.
    Proceedings of the National Academy of Sciences. 2019; 11617450-17459
    • Liu C.
    • Zheng S.
    • Jin R.
    • et al.
    The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    CANCER LETT. 2020; 47095-105
    • Lal N.
    • White B.S.
    • Goussous G.
    • et al.
    KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    CLIN CANCER RES. 2018; 24224-233
    • Luis A.
    • Diaz D.T.L.T.
    KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
    J CLIN ONCOL. 2018; (4_suppl)S877
    • Samstein R.M.
    • Lee C.H.
    • Shoushtari A.N.
    • et al.
    Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
    NAT GENET. 2019; 51202-206
    • Davoli T.
    • Uno H.
    • Wooten E.C.
    • Elledge S.J.
    Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    SCIENCE. 2017; 355
    • Li L.
    • Li M.
    • Wang X.
    Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    DNA REPAIR. 2020; 88102785
    • Wang B.
    • Niu D.
    • Lai L.
    • Ren E.C.
    p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1.
    NAT COMMUN. 2013; 42359
    • Cortez M.A.
    • Ivan C.
    • Valdecanas D.
    • et al.
    PDL1 Regulation by p53 via miR-34.
    J Natl Cancer Inst. 2016; 108
    • Zhu K.
    • Wang J.
    • Zhu J.
    • Jiang J.
    • Shou J.
    • Chen X.
    p53 induces TAP1 and enhances the transport of MHC class I peptides.
    ONCOGENE. 1999; 187740-7747
    • Owen-Schaub L.B.
    • Zhang W.
    • Cusack J.C.
    • et al.
    Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
    MOL CELL BIOL. 1995; 153032-3040
    • Janjigian Y.Y.
    • Sanchez-Vega F.
    • Jonsson P.
    • et al.
    Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
    CANCER DISCOV. 2018; 849-58
    • Sun C.
    • Mezzadra R.
    • Schumacher T.N.
    Regulation and Function of the PD-L1 Checkpoint.
    IMMUNITY. 2018; 48434-452
    • Chakrabarti J.
    • Holokai L.
    • Syu L.
    • et al.
    Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
    Oncotarget. 2018; 937439-37457

Plaats een reactie ...

Reageer op "Moleculaire veranderingen plus PD-L1 waarden geven een voorspelling voor de effectiviteit van behandelingen met immunotherapie bij patiënten met gastro-oesofageale adenocarcinoom"


Gerelateerde artikelen
 

Gerelateerde artikelen

Moleculaire veranderingen >> Bloedtest kan vroeg darmkanker >> In bloed circulerend DNA na >> Analyse van gegevens van in >> Total body MRI gevolgd door >> Coloscopie met G-eye balloon >> Diagnose: IOBT - FOB test >> Histologische subtype - karakter >> Lynchsyndroom, genafwijking >> Fecale Immunochemische Test >>